- Home
- SBGI vs PHVS Comparison
SBGI vs PHVS Comparison
Compare SBGI & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBGI
- PHVS
- Stock Information
- Founded
- SBGI 1986
- PHVS 2015
- Country
- SBGI United States
- PHVS Netherlands
- Employees
- SBGI N/A
- PHVS N/A
- Industry
- SBGI Broadcasting
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- SBGI Industrials
- PHVS Health Care
- Exchange
- SBGI Nasdaq
- PHVS Nasdaq
- Market Cap
- SBGI 997.6M
- PHVS 1.0B
- IPO Year
- SBGI 1995
- PHVS 2021
- Fundamental
- Price
- SBGI $14.92
- PHVS $17.11
- Analyst Decision
- SBGI Buy
- PHVS Strong Buy
- Analyst Count
- SBGI 5
- PHVS 5
- Target Price
- SBGI $20.10
- PHVS $41.60
- AVG Volume (30 Days)
- SBGI 195.5K
- PHVS 49.2K
- Earning Date
- SBGI 02-26-2025
- PHVS 11-13-2024
- Dividend Yield
- SBGI 6.78%
- PHVS N/A
- EPS Growth
- SBGI N/A
- PHVS N/A
- EPS
- SBGI N/A
- PHVS N/A
- Revenue
- SBGI $3,370,000,000.00
- PHVS N/A
- Revenue This Year
- SBGI $14.93
- PHVS N/A
- Revenue Next Year
- SBGI N/A
- PHVS N/A
- P/E Ratio
- SBGI N/A
- PHVS N/A
- Revenue Growth
- SBGI 3.12
- PHVS N/A
- 52 Week Low
- SBGI $11.13
- PHVS $15.21
- 52 Week High
- SBGI $18.45
- PHVS $33.00
- Technical
- Relative Strength Index (RSI)
- SBGI 42.68
- PHVS 38.75
- Support Level
- SBGI $14.26
- PHVS $17.11
- Resistance Level
- SBGI $15.10
- PHVS $18.70
- Average True Range (ATR)
- SBGI 0.55
- PHVS 1.10
- MACD
- SBGI 0.03
- PHVS -0.07
- Stochastic Oscillator
- SBGI 40.31
- PHVS 34.65
About SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their content to pay-TV distributors.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.